Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Eli Lilly, Takeda end Arxxant deal

LLY and Takeda (Tokyo: 4502) agreed to terminate a 2003 deal to

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE